Tvardi Therapeutics (TVRD) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

TVRD · Stock Price

USD 4.21-21.40 (-83.56%)

Market Cap: $39.3M

Historical price data

Market Cap: $39.3MFounded: 2017Employees: 11-50HQ: Houston, United States

Sector Ranking#305 in Small Molecule Drugs #133 in Oncology (General)

Overview

Tvardi Therapeutics is a Houston-based biotech focused on developing oral STAT3 inhibitors to treat fibrosis-driven, inflammatory, and proliferative diseases. Founded in 2017, the company has progressed its lead asset, TTI-101, into Phase 2 trials for IPF and liver cancer. Its strategy leverages a novel, direct STAT3 inhibition platform with broad therapeutic potential, recently bolstered by a 2025 merger with Cara Therapeutics to enhance resources and pipeline depth.

FibrosisOncologyInflammatory Diseases

Technology Platform

Oral small molecule inhibitors designed to directly bind and inhibit STAT3, a master regulator transcription factor involved in fibrosis, inflammation, and cancer.

Funding History

2

Total raised:$110M

Series B$80MSpindletop CapitalJan 15, 2022

Series A$30MSpindletop CapitalJun 15, 2020

Opportunities

TTI-101 addresses multi-billion dollar markets in IPF and HCC with no direct oral STAT3 competitors.

Positive Phase 2 data could trigger partnerships, premium pricing, and rapid expansion into other STAT3-driven fibrotic and inflammatory diseases.

Risk Factors

High clinical risk as valuation hinges on unproven efficacy of TTI-101.

Limited cash runway necessitates dilutive financing.

Post-merger integration and execution on divesting non-core assets add operational complexity.

Competitive Landscape

Competes indirectly with upstream pathway inhibitors (JAK/IL-6 inhibitors) and standard-of-care drugs. Holds a first-mover advantage with a direct, oral STAT3 inhibitor in Phase 2, but faces potential future competition from other STAT3-targeting modalities in development.